Background: In contrast to the well-accepted benefits of moderate exercise, recent research has suggested potential deleterious effects of repeated marathon running on the cardiovascular system. We thus performed a comprehensive analysis of markers of subclinical vascular damage in a cohort of runners having finished multiple marathon races successfully.
Introduction
Since the first evidence on potential myocardial damage after prolonged strenuous exercise had emerged in the 1980s, 1,2 numerous subsequent studies have reported on elevations of cardiac biomarkers such as circulating troponin or brain natriuretic peptide following marathon running (reviewed in Gresslien and Agewall) . 3 In addition, further studies have suggested that in apparently healthy runners chronic alterations such as paradoxically increased coronary artery calcium scores 4 or otherwise unexplained myocardial fibrosis 5 may also be observed, interpreted by some as a potential negative consequence of lifelong exposition to endurance exercise, at least in predisposed individuals. 6 Together with epidemiological evidence on a lack of mortality benefits in runners performing high exercise intensities and volumes, 7 the theory of a J-shaped curve regarding the effects of regular exercise has been proposed; while moderate activities show optimal benefit, exercising several hours per day at higher intensities appears to approach similar mortality rates than sedentary behaviour. 8 On a vascular level, early predictors of potential detrimental effects include increased arterial stiffness and endothelial dysfunction. 9 A variety of methods nowadays allow for rapid clinical assessment of these important prognostic markers, representing an excellent opportunity to evaluate whether repeated marathon running may independently induce subclinical vessel alterations. However, a comprehensive analysis of the impact of repeated marathon running on established parameters of peripheral subclinical vascular damage has not been performed yet. Therefore, in light of the debate mentioned above, this study aimed at evaluating the prevalence of subclinical vascular impairment in clinically healthy marathon runners with low cardiovascular risk profiles and to link the findings to individual training histories and physical fitness parameters.
Methods

Study design and population
The present work was a substudy of the EnzyMagictrial (ClinicalTrials.gov identifier: NCT01916408). This prospective randomised controlled trial evaluated the effects of oral hydrolytic enzymes and flavonoids on markers of inflammation and upper respiratory illness following the Munich marathon. Details of the study protocol have been outlined previously, 10 and the main results have been published recently. 11 Briefly, healthy male marathon runners free of regular medication, cardiovascular or other diseases were randomly allocated 1:1 to a group receiving a drug rich in flavonoids and hydrolytic enzymes (Wobenzym, MUCOS Pharma, Berlin, Germany) one week before participation in the Munich marathon or to a group receiving placebo; medication was continued for another two weeks after the race. As part of the baseline visit of the trial five weeks before the marathon, runners underwent an extensive clinical assessment, including detailed medical and training history, electrocardiogram, clinical chemistry, echocardiogram, carotid ultrasound and cardiopulmonary exercise testing (CPET). Participants were excluded in case of pathological findings during this visit.
In the main trial, a total of 162 participants had presented for the baseline visit, and training histories, maximal exercise capacities and intima-media-thickness as outcomes of the substudy presented here were assessed during this visit (see below). A subgroup of 97 runners again presented post-race after a washout phase of the study medication of four weeks for the assessment of further outcomes such as arterial stiffness and endothelial function (see also below), thus representing the population included in the present analysis. The other participants were not available for complete follow-up examinations due to lack of time. All participants gave written informed consent prior to study participation, and the study including this substudy was approved by the ethical board of the medical faculty of the Technical University of Munich (reference number 5820/13). The study protocol confirms to the ethical guidelines of the 1975 Declaration of Helsinki.
Baseline parameters
Participants gave a detailed medical history with a particular focus on potential risk factors for cardiovascular disease. Regarding training history, patients completed a standardised questionnaire on the following parameters: number of previously finished half, full or ultramarathons, weeks of intensive preparation for the Munich marathon, average weekly and annual training km. Height and weight were measured according to standard techniques, and body mass index was calculated by dividing weight in kilograms through the square of height in meters. Venous blood samples were taken from an antecubital vein after at least 12 h of fasting and analysed for blood lipids, glucose and kidney function.
CPET (Cortex, Leipzig, Germany) was performed by experienced medical staff on treadmills (h/p cosmos, Traunstein, Germany) using a standardised ramp protocol with a target duration of 10-12 min. The test started with a resting period of three minutes, followed by an initial velocity of 6, 8 or 10 km/h over three minutes (depending on the intended pace during the marathon) and an increase of 2 km/h per minute until volitional exhaustion. VO 2peak was calculated as the average of the three highest measurements within the final minute. The finishing times of the Munich marathon were measured by the organisers of the race using an automatic tracking system.
Vascular assessments
Intima-media-thickness (IMT) was measured by carotid ultrasound using an 11 MHz transducer with software for automated assessment (IE33; Qlab, Philips, Amsterdam, The Netherlands). Two measurements were performed in the end-diastolic phase from both antero-and posterolateral views on both sides, 1 cm proximal to the bifurcation over a length of 2 cm; the average value was calculated as the mean of left and right IMT. In addition, the presence of plaques was documented.
Regarding parameters of arterial stiffness and endothelial function, all examinations were performed in a quiet room in a supine position after at least 10 min of resting and after >12 h of fasting between 08:00-10:00. All participants underwent examinations in the same order according to the following paragraphs.
Pulse wave velocity (PWV) as well as ankle-brachial index (ABI) were assessed using a validated combined oscillometric and photo-plethysmographic technique (Vascular Explorer, enverdis, Jena, Germany). Details of these methods have been described previously. 12 Briefly, using inflatable cuffs with high fidelity sensors placed on both arms and legs, aortic PWV is calculated from the time difference of the direct and the reflected pressure wave, and carotid-femoral PWV is subsequently calculated automatically with internal algorithms. ABI is measured using the cuffs in combination with photoplethysmographic sensors with signals being detected distally at fingers and toes. The signals disappear after inflation when exceeding systolic pressure, and reappear after deflation. This procedure is applied to both sides, and ABI is then calculated as the ratio of ankle pressure to mean of right and left arm pressures.
Wave reflection analysis was performed by means of applanation tonometry, using the validated system SphygmoCor (AtCor Medical, Sydney, Australia). Details of this method have also previously been described. 13 Briefly, from the pressure wave of the radial artery the central blood pressure wave is accurately estimated using a generalised transfer function. The radial artery pressure waves were calibrated according to non-invasively measured systolic and diastolic blood pressures measured in the brachial artery. The following parameters are calculated: central systolic and diastolic blood pressure, pulse pressure (difference between central systolic and diastolic blood pressure), augmentation pressure (pressure added to the incident wave by the returning reflected pulse wave), and augmentation index (AIx) as a key outcome of this technique (calculated as the ratio between augmentation and pulse pressure, expressed as percentage).
Endothelial function was measured using an invasively validated finger plethysmography technique (EndoPAT 2000, Itamar Medical, Caesarea Ind. Park, Israel). Details of this method have again previously been described. 14 Briefly, beat-to-beat plethysmographic recordings of the finger arterial pulse wave amplitude are captured with pneumatic probes. A pressure cuff on the arm is inflated to values above systolic pressure and deflated again after 5 min, causing reactive hyperaemia with an increase in pulsatile arterial volume changes. Since the contralateral arm is used as an internal control, the difference in changes in pulse waves (registered every 30 s) is calculated as the reactive hyperaemia index (RHI), indicating either preserved or, in case of attenuated reaction to hyperaemia, impaired endothelial function.
Statistical analysis
Data were tested for normal distribution using the Shapiro-Wilks test and graphical analysis and are presented as mean AE standard deviation or range if normally distributed, or as median (25 th -75 th percentile or range) if not normally distributed. Accordingly, associations between vascular outcomes and parameters related to exercise capacity and training history were analysed using either Pearson's correlation coefficient or Spearman's rank correlation coefficient. Similarly, comparisons between subgroups were performed using either the Student's t-test or the MannWhitney U test for independent data. The KruskalWallis-test was used for the between-group comparisons (tertiles of number of previously completed marathon races) regarding the amount of reactive vessel dilatation. As the present study is of an exploratory character, we did not perform multiple test adjustments according to acknowledged recommendations.
15 A two-sided significance level of a ¼ 0.05 was chosen for all tests. Data analysis was performed using SPSS version 23.0 (IBM, Chicago, USA) and R version 3.3.0 (R Foundation for Statistical Computing, Vienna, Austria).
Results
Baseline characteristics of the study population as well as results from the initial CPET and the Munich marathon are summarised in Table 1 . All runners were never-smokers. A positive family history for cardiovascular disease was present in 18 participants. Prior to the current marathon, participants had successfully finished a median of eight (25 th -75 th percentile 4-15; range 1-500) half marathons (n ¼ 67), six (2-12; 1-100) full marathons (n ¼ 87) and three (2-9; 1-40) ultramarathons (n ¼ 14); numbers include double counts. This resulted in a median of 11 (4-25; 1-509) previously completed running events with a wide range of previous competitional engagement.
Runners showed normal mean values for all vascular parameters with respect to established reference ranges (see Table 2 ). Significant associations were found for age with IMT (r ¼ 0.531; p < 0.001), AIx (r ¼ 0.593; p < 0.001) and PWV (r ¼ 0.357; p < 0.001), but not with ABI (r ¼ 0.104; p ¼ 0.309) or RHI (r ¼ 0.120; p ¼ 0.242). These associations remained significant independent of adjustment for VO 2peak , finishing time and number of previously completed races. Weak, but significant inverse associations were also observed for VO 2peak with IMT and AIx (r ¼ À0.308; p ¼ 0.002 each), but significance was lost after adjustment for age (IMT: Table S1 for complete results).
No differences in any of the key vascular parameters were observed between runners having finished at least one ultramarathon (n ¼ 14) and those having finished only half or full marathons prior to the current race (n ¼ 83; see Table 3 ). Increased IMT (>0.9 mm), carotid Reference values are age-and blood-pressure-dependent. The cut-off values listed for pulse wave velocity, pulse pressure and augmentation pressure have been derived from studies on healthy reference populations covering similar age ranges than our cohort. For augmentation index, the 95 th upper prediction limit according to the mean age of the study population has been chosen as cut-off value. plaques or both were present in n ¼ 12 (12%) runners. These runners had finished more previous races (26 ) than runners with normal IMT and absence of plaques (10 (4-22) ; p ¼ 0.072), but were also significantly older (54 AE 8 vs 43 AE 10 years; p < 0.001). Figure 1 shows the median time courses of reactive vessel dilatation as assessed with the EndoPAT-System according to tertiles of number of previously completed races. No significant between-group differences were observed during the whole course of the reaction (p for maximum dilatation ¼ 0.669; p > 0.05 for all other time points).
Discussion
In this cohort of healthy middle-aged male runners, no significant impact of exercise capacity, training history, number of previously completed half-, full or ultramarathon races or marathon finishing time on markers of subclinical vascular impairment was observed. Significant associations were found for age only, with a higher prevalence of abnormal values for IMT, AIx and PWV in older runners, independent of exerciserelated parameters. These findings indicate that repeated exposition to strenuous exercise does not seem to pose an independent risk factor for premature vascular impairment beyond the influence of age. The debate whether strenuous exercise including marathon running may result in adverse effects on the cardiovascular system was primarily based on observations on cardiac alterations. In addition to the findings mentioned in the introduction, La Gerche et al. observed a temporal impairment of right ventricular function in response to marathon running, 23 and in a rat model, atrial fibrosis following an intensive exercise programme was reported. 24 It was thus hypothesised that repeated exercise-induced cardiac strain, accompanied by insufficient regeneration between training sessions and races, may result in persistent structural and functional cardiac damage over the long-term. 25 A similar theory has been proposed for the influence of marathon running on the vasculature. Basically, alongside cardiac enlargement in response to longstanding endurance exercise, runners are believed to also develop enlarged arteries with decreased wall thickness, termed by some as the 'athlete's artery'. 26 These vessels may be prone to both positive and negative adaptations following different exercise volumes and intensities. 27 Persistently increased levels of inflammatory markers and matrix metalloproteinases have been observed in runners and have been proposed to potentially contribute to an increase in arterial stiffness and vascular fibrosis. 28 In addition, repetitive elevations in cardiac output during exercise as well as increased stroke volume during resting in well-trained athletes are associated with higher volume and pressure loads on the vasculature. This may cause fatigue and fragmentation of elastin fibres with subsequent vascular fibrotic remodelling induced by stimulated macrophages and fibroblasts, resulting in an increase in arterial stiffness and in endothelial dysfunction over time. 29 According to these considerations, several studies have examined the vascular effects of marathon running, either as an acute response to the race itself or as chronic adaptations to longstanding endurance exercise. Regarding acute effects, Vlachopoulos et al. 30 described a significant decrease of AIx as assessed with the SphygmoCor device in 20 male runners immediately post-race, indicating at least a temporal beneficial effect of strenuous exercise, whereas PWV remained unchanged. In contrast to these findings, Burr et al. 31 studied 26 ultra-marathon runners and found, using applanation tonometry from a different device, that large artery compliance was impaired post-race, whereas in a second trial PWV temporally decreased during the race in nine runners. 32 Findings from our group on post-race changes in AIx in 49 marathon runners were in line with the study by Vlachopoulos et al. in confirming a significant decrease in AIx as assessed with the SphygmoCor device. 33 Interestingly, MicroRNA-126 as a marker of endothelial damage was recently found to be elevated after marathon running, indicating potential mechanisms of vessel reactivity during strenuous exercise on a molecular level. 34 Regarding chronic alterations, Vlachopoulos et al. 30 compared 49 marathon runners (86% male) with 46 age-matched controls performing only recreational exercise and observed slightly, but significantly higher aortic pressures and PWV in runners, but no differences in AIx. However, the mean PWV was even lower in these runners (6.89 AE 1.00 m/s) compared with our cohort, and the subjects were also younger (38 AE 9 years). Radtke et al. 35 evaluated the blood-pressure independent cardio-ankle vascular index and also PWV in recreational athletes (n ¼ 16), marathon runners (n ¼ 19) and ultra-endurance athletes (n ¼ 16; all males) and observed no group differences; similar to our study the only independent predictor in this cohort was age. The authors concluded that (ultra)marathon running had no independent impact on arterial stiffness. Knez et al. 36 compared ultraendurance athletes (n ¼ 44) with matched controls (n ¼ 44; 80% male) and found no difference with respect to AIx and other indices of central haemodynamics. In contrast, Burr et al. 37 reported a significant reduction of large, but not small artery compliance in 18 male ultramarathon runners compared with 35 matched controls. Finally, Taylor et al. 38 recently observed no difference between marathon runners (n ¼ 42, 50% female) and their sedentary counterparts with respect to IMT and central systolic and augmentation pressures; similar to our findings, these outcomes were primarily associated with increasing age.
In summary, results were equivocal in these studies, which may be attributed to the application of different methods and the evaluation of rather small and heterogeneous populations in different age ranges. However, our findings in a well-characterised and much larger cohort of runners are in line with the majority of previous observations in not supporting an independent detrimental effect of (ultra)marathon running on vessel integrity. It should, however, be noted that repeated marathon running does also not appear to induce beneficial effects on subclinical vascular structure and function.
Limitations
The major limitation is the lack of a non-running control group. However, our cohort was substantially larger than in previous studies and we provide extensive information on training history and objective exercise capacity, overcoming this limitation by detailed correlation and subgroup analyses. The ranges of training histories, exercise capacity and marathon performance were large in our cohort, indicating that in some runner's exposition to training might not have been long or intensive enough to induce vascular alterations. In the main EnzyMagic trial, 50% of runners were allocated to a flavonoid-rich drug with potential impact on vessel structure and function. However, when comparing vascular parameters between participants that were originally randomised to verum with those having taken placebo, no differences were noted (see Supplementary Material, Table S2 ). Furthermore, 40% of participants in the original study were not available for the present analysis, and the results cannot be transferred to female runners.
Conclusion
In this cohort of healthy male middle-aged marathon runners free of cardiovascular disease, no associations between parameters indicating a longstanding history of endurance exercise and markers of subclinical vascular damage were observed. Age was the only predictor of the majority of these markers; therefore, repeated marathon running per se does not pose an independent risk factor for the development of premature vascular dysfunction subsequently leading to atherosclerosis. Instead, running multiple marathons appears safe from a vascular perspective in having a neutral effect on subclinical markers of vascular impairment.
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